Shamloo Lab News

We are pleased to announce that CuraSen Therapeutics Inc, a Stanford originated Biotech founded by Dr. Mehrdad Shamloo in 2017,  has successfully closed  $54.5 Million Series A Financing. CuraSen Therapeutics Inc. is developing drugs targeting a novel mechanism in CNS disorders with ultimate goal of improving the quality of life of people with neurodegenerative disorders. Additional co-founders include Robert Booth, PhD, former chief executive officer of ViroBay, along with Anthony Ford, PhD, chief executive officer, CuraSen and Ms. Kathleen Sereda Glaub, executive chair, CuraSen. For more information, visit www.curaseninc.com.

Read More:

Fiercebiotech

PRNewswire